Grant Search

Cancer Type

Keyword Search  

Categories

Grant Amount
>=

<=





Results: 65

Advanced RNAi therapeutics for DIPG

Diffuse intrinsic pontine glioma (DIPG) is a form of brain tumor that arises in the brainstem of children and is nearly 100% fatal with a median survival of 9-12 months after diagnostic. The location of these highly infiltrating tumors in the ventral pons precludes surgical resection and clinical trials with different ...

Short-pulse ultrasound delivery of panobinostat for the treatment of diffuse ...

Children with diffuse intrinsic pontine gliomas (DIPGs) have a 2-year survival rate of less than 10%. Compared to other brain cancers, DIPG is particularly difficult to treat because it spreads behind an intact blood-brain barrier (BBB) affecting healthy developing paediatric brain tissue. There are currently no effective treatments for this disease. ...

study of radiotherapy and concurrent bevacizumab temozolamide followed by bevacizumab. ...

Five-year overall survival in children with high-grade glioma (HGG) and diffuse, intrinsic brainstem glioma (DIPG) are  approximately 25% and 10%, respectively 1-3.  Achieving cure for all children with HGG and DIPG  remains a major goal of pediatric neuro-oncology. DIPGs are infiltrative gliomas, and have typically been found to be &...

Polyamine pathway metabolism as a novel therapeutic option for Diffuse ...

Diffuse intrinsic pontine glioma (DIPG) is the most aggressive of all childhood cancers. Standard treatment with radiotherapy is only palliative and chemotherapy has been found ineffective. Polyamines are organic compounds essential for key functions of living cells. They can be made by human cells but also generated from intestinal microorganisms ...

MRI Guided Focused Ultrasound: Targeted Drug Delivery in Diffuse Intrinsic ...

Hypothesis & Anticipated Results Diffuse Intrinsic Pontine Glioma, (DIPG) is a fatal cancer and the leading cause of death from  brain tumours in young children. Despite numerous existing chemotherapeutic agents and  promising new molecular therapies, one overriding challenge remains: to overcome the blood  brain barrier (BBB) and ...